EA
XLRN

Emerald Acquisition’s Acceleron Pharma XLRN Stock Holding History

Emerald Acquisition’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$561K Buy
15,512
+6,390
+70% +$212K ﹤0.01% 2399
2016
Q2 		$310K Buy
+9,122
New +$297K ﹤0.01% 2632

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Emerald Acquisition's XLRN Position: Q3 2016 in Review

Emerald Acquisition increased its Acceleron Pharma (XLRN) stake by 70% in Q3 2016, buying an estimated $212K and bringing the position to 15,512 shares worth $561K. The position accounts for ﹤0.01% of the portfolio, ranked #2399.

Emerald Acquisition first reported a position in XLRN in Q2 2016 and has held it in 2 quarters since. 138 funds tracked by Wall St. Rank hold XLRN as of Q3 2016.

  • Emerald Acquisition held 15,512 shares of Acceleron Pharma worth $561K as of Q3 2016.
  • Emerald Acquisition bought 6,390 Acceleron Pharma shares in Q3 2016, an estimated $212K.
  • Acceleron Pharma made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2399 holding.
  • Emerald Acquisition first reported a position in Acceleron Pharma in Q2 2016 and has held it in 2 quarters since.
  • 138 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.